A new drug, LCZ696, may mark a significant improvement in heart failure treatments. The drug acts as both an angiotensin receptor blocker and utilizes a neprilysin inhibitor, which limits the hormones that cause blood vessel constriction. Scott Solomon, professor of medicine at Brigham and Women’s Hospital, is quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure